| 產品編號 | bs-0438R-PE-Cy5 |
| 英文名稱 | Rabbit Anti-AT2R/PE-Cy5 Conjugated antibody |
| 中文名稱 | PE-Cy5標記的血管緊張素Ⅱ受體1抗體 |
| 別 名 | AG2S; Agtr 1; Agtr1; AGTR1_HUMAN; Agtr1a; AGTR1B; Ang II; Angiotensin II receptor type 1; Angiotensin II type 1 receptor; Angiotensin II type-1 receptor; Angiotensin receptor 1; Angiotensin receptor 1B; AT 1B; AT 1r; AT-1B; AT-1r; AT1; At1a; AT1AR; AT1B; AT1BR; AT1R; AT2R1; AT2R1A; AT2R1B; HAT1R; Type 1 angiotensin II receptor; Type 1B angiotensin II receptor; Type-1 angiotensin II receptor. |
| 規格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領域 | 腫瘤 心血管 細胞生物 免疫學 血管內皮細胞 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Mouse, Rat, (predicted: Human, ) |
| 產品應用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 41kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human AT2R |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 癈 for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20癈. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 癈. |
| 產品介紹 |
background: Angiotensin II (Ang II) is an important physiological effector of blood pressure and volume regulation through vasoconstriction, aldosterone release, sodium uptake and thirst stimulation. Although Ang II interacts with two types of cell surface receptors, AT1 and AT2, most of the major cardiovascular effects seem to be mediated through AT1. Molecular cloning of the AT1 protein has shown it to be a member of the G protein-associated seven transmembrane protein receptor family. Ang II treatment of cells results in activation of several signal transduction pathways as evidenced by tyrosine phosphorylation of several proteins and induction of others. PLC?is phosphorylated after 30 seconds of treatment with Angiotensin II, indicating this as an early signal transduction event. Ang II treatment also stimulates phosphorylation of Shc, FAK and MAP kinases, and induces MKP-1, indicating stimulation of growth factor pathways. Ang II stimulation through AT1 has been shown to activate the JAK/Stat pathway involving a direct interaction between JAK2 and AT1 as demonstrated by coimmunoprecipitation. The AT1 receptor has no cytoplasmic kinase domain, but is able to function as a substrate for Src kinases and has several putative phosphorylation sites. Function: Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Subunit: Interacts with MAS1 (Probable). Interacts with ARRB1 (By similarity). Subcellular Location: Cell membrane; Multi-pass membrane protein. Tissue Specificity: Liver, lung, adrenal and adrenocortical adenomas. Post-translational modifications: C-terminal Ser or Thr residues may be phosphorylated. DISEASE: Defects in AGTR1 are a cause of renal tubular dysgenesis (RTD). RTD is an autosomal recessive severe disorder of renal tubular development characterized by persistent fetal anuria and perinatal death, probably due to pulmonary hypoplasia from early-onset oligohydramnios (the Potter phenotype). Similarity: Belongs to the G-protein coupled receptor 1 family. Database links: Entrez Gene: 185 Human Entrez Gene: 11607 Mouse Entrez Gene: 11608 Mouse Omim: 106165 Human SwissProt: P30556 Human SwissProt: P29754 Mouse SwissProt: P29755 Mouse Unigene: 477887 Human Unigene: 728754 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 主要用于心、腦、血管病及腫瘤的基礎研究。 |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
